^
Association details:
| Biomarker: | TP53 A159V |
|---|---|
| Cancer: | Burkitt Lymphoma |
| Drug: | PZ01 (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Published date:
02/25/2021
Excerpt:
A male patient was diagnosed with BL-PTLD...Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V...We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine....Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date.
Secondary therapy:
cyclophosphamide + fludarabine oral
DOI:
10.1177/0963689721996649
